Condition Guide

Peptides for Cognitive Decline

Semax, Selank, and related Russian-developed nootropic peptides have been investigated for decades in cognitive decline, stroke recovery, and attention disorders.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

How peptides help

Semax (ACTH 4-10 analog) and Selank (tuftsin analog) upregulate BDNF and NGF, modulate monoamine metabolism, and support synaptic plasticity. Both are approved in Russia for cognitive and anxiety indications.

Peptides researched for cognitive decline

State of the evidence

Russian clinical data exists for both Semax and Selank. Western controlled trials are sparse. Safety data is favorable; efficacy outside Russian literature is not well characterized.

Frequently asked

Are Semax and Selank available in the US?

They are not FDA approved and are classified as research chemicals in the U.S. Availability from reputable sources is limited.

Related articles & guides

Related conditions